{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:17:57Z","timestamp":1788380277038,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study evaluated whether an addition of bevacizumab to erlotinib improves clinical outcomes in patients with advanced <jats:italic>EGFR<\/jats:italic>\u2010mutated non\u2013small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is an open\u2010label, multicenter, randomized Phase 2 study in South Korea. Chemona\u00efve patients with Stage IIIB\/IV NSCLC with <jats:italic>EGFR<\/jats:italic> 19 deletion or L858R mutation were eligible. Asymptomatic brain metastasis (BM) was enrolled without local treatment. Patients received either erlotinib plus bevacizumab or erlotinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between December 2016 and March 2019, 127 patients were randomly assigned to receive erlotinib plus bevacizumab (<jats:italic>n<\/jats:italic>\u00a0=\u00a064) or erlotinib (<jats:italic>n<\/jats:italic>\u00a0=\u00a063). Fifty\u2010nine (46.5%) patients had baseline BM. Fewer patients in the erlotinib plus bevacizumab arm received radiotherapy for BM than in the erlotinib arm (10.3% vs. 40.0%). A trend toward longer progression\u2010free survival (PFS) was observed in the erlotinib plus bevacizumab arm compared with the erlotinib alone arm; however, it was not statistically significant (median PFS, 17.5\u00a0months vs. 12.4\u00a0months; hazard ratio [HR],\u00a00.74; 95% CI, 0.51\u20131.08; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.119). The unplanned subgroup analysis showed a longer PFS with erlotinib plus bevacizumab in patients with BM (median PFS, 18.6\u00a0months vs. 10.3\u00a0months; HR,\u00a00.54; 95% CI, 0.31\u20130.95; <jats:italic>p<\/jats:italic>\u00a0=\u00a0.032). Grade 3 or worse adverse events occurred in 56.6% of the erlotinib plus bevacizumab arm and 20.6% of the erlotinib arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although it was not statistically significant, a trend to improvement in PFS was observed in patients with erlotinib plus bevacizumab compared to erlotinib alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>A randomized Phase 2 study compared erlotinib with or without bevacizumab in previously untreated patients with advanced non\u2013small cell lung cancer with <jats:italic>EGFR<\/jats:italic> mutation. The erlotinib plus bevacizumab failed to improve median progression\u2010free survival compared with the erlotinib alone. However, the progression\u2010free survival benefit from erlotinib plus bevacizumab was found in patients with brain metastasis with no severe hemorrhagic adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34553","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T07:18:02Z","timestamp":1669879082000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non\u2013small cell lung cancer with <i>EGFR<\/i> mutation"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0180-189X","authenticated-orcid":false,"given":"Youngjoo","family":"Lee","sequence":"first","affiliation":[{"name":"Center for Lung Cancer National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-2195","authenticated-orcid":false,"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Chungbuk National University Hospital  Cheongju Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-7063","authenticated-orcid":false,"given":"Keon Uk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Keimyung University Dongsan Hospital  Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon Kook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyae Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo\u2010Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Young","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Radiology National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jin","family":"Yoon","sequence":"additional","affiliation":[{"name":"Center for Lung Cancer National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2010Youn","family":"Han","sequence":"additional","affiliation":[{"name":"Center for Lung Cancer National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"36","article-title":"Targeted therapy for non\u2010small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan BA","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.4235"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa040938"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(09)70364\u2010x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0810699"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.06.081"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.16"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0227"},{"key":"e_1_2_9_12_1","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor\u2010blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria Petit A","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30634-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30035\u2010x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.005"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.006"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1847"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6758"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.010"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010021\u201000794\u20106"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.0616"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010010\u20100200\u20102"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815y.0000000045"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100274"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010015\u20101966\u20100"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.003"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32503"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:32:27Z","timestamp":1760290347000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cncr.34553"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34553","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"2022-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}